Invention Application
- Patent Title: COMPOUNDS THAT INHIBIT MCL-1 PROTEIN
-
Application No.: US16123030Application Date: 2018-09-06
-
Publication No.: US20190016736A1Publication Date: 2019-01-17
- Inventor: Sean P. BROWN , Yunxiao LI , Mike Elias LIZARZABURU , Brian S. LUCAS , Nick A. PARAS , Joshua TAYGERLY , Marc VIMOLRATANA , Xianghong WANG , Ming YU , Manuel ZANCANELLA , Liusheng ZHU , Ana GONZALEZ BUENROSTRO , Zhihong LI
- Applicant: AMGEN INC.
- Applicant Address: US CA Thousand Oaks
- Assignee: Amgen Inc.
- Current Assignee: Amgen Inc.
- Current Assignee Address: US CA Thousand Oaks
- Main IPC: C07D513/10
- IPC: C07D513/10 ; C07D513/08

Abstract:
Provided herein are compounds that are useful intermediates that may used to synthesize myeloid cell leukemia 1 protein (Mcl-1) inhibitors. Also provided are Mcl-1 inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.
Information query